V114 is an investigational vaccine currently being evaluated for its ability to provide protection against pneumococcal disease caused by serotypes contained in the vaccine.
For further information on clinical trials, please refer to:
Phase 1 clinical trials test the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital. The goals are to determine:
If the medicine or vaccine is safe
If there are any side effects
How the medicine is broken down by and discharged from the body
How much medicine is needed and how often
For a vaccine, researchers see if it causes the desired response from the body’s immune system
Phase 1 trials an take from six months to one year to complete.
Phase 2
Phase 2 clinical trials test the vaccine or medicine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy. The goals of this phase are to determine:
How well the medicine or vaccine works
If the medicine or vaccine is safe
If there are any side effects
How much of the medicine or vaccine is needed and how often
Phase 2 trials can take from six months to one year or more to complete.
Phase 3
Phase 3 clinical trials can test the medicine or vaccine in 1,000 to 5,000 patient volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices. Researchers closely monitor patients at regular intervals to:
Confirm that the medication or vaccine is effective
Identify and monitor side effects
Compare the medicine or vaccine to commonly used treatments
Phase 3 trials can take from one to four years to complete, depending on the disease, length of study and number of volunteers.
Under review
The application has been submitted to the regulatory authorities for review.
No Duty to Update
The information contained in this chart was current as of May 3, 2022. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after May 3, 2022.
The chart reflects the company research pipeline as of May 3, 2022.
Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.
